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Abstract 
Background: Obesity is a recognized risk factor for various cardiometabolic diseases and several indices are used 
clinically to assess overall cardiometabolic risk. This study aims to determine the sensitivity of six anthropometric 
indices [Body mass index (BMI), waist, waist‑to‑hip ratio (WHR), waist‑to‑height ratio (WHtR), body adiposity index 
(BAI) and visceral adiposity index (VAI)] in determining diabetes mellitus type 2, coronary heart disease, dyslipidemia, 
hypertension and metabolic syndrome (MetS) in Saudi adults recruited from two independent cohorts (2008–2009 
and 2013–2014).
Methods: A total of 6,821 Saudi adults [2008–2009, N = 3,971 (1,698 males and 2,273 females); 2013–2014, N = 2,850 
(926 males and 1,924 females)] aged 18–70 years old were included in this descriptive, cross‑sectional study. Anthro‑
pometrics were obtained and fasting blood samples analyzed for glucose and lipids. BMI, WHR, WHtR, BAI and VAI 
were computed mathematically.
Results: VAI was the most sensitive index in determining DMT2 (AUC 0.72; p < 0.001) in the 2008–2009 cohort and 
MetS (AUC = 0.84; p < 0.001) in the 2013–2014 cohort. WHR was most discriminating for CHD in both cohorts (AUC 
0.70 and 0.84 for 2008–2009 and 2013–2014, p values <0.001, respectively). WHtR was most sensitive but rather mod‑
est in determining hypertension (AUC 0.66; p < 0.001), while waist circumference was most sensitive for dyslipidemia 
(AUC 0.72; p < 0.001) in the 2008–2009 cohort and MetS (AUC 0.85; p < 0.001) in the 2013–2014 cohort. BAI was the 
least sensitive adiposity index.
Conclusion: Sensitivity of adiposity indices regarding cardiometabolic diseases highlight the importance of body fat 
distribution in determining overall cardiometabolic risk, with indices involving abdominal obesity being more clini‑
cally significant than BMI and BAI. The sensitivity of these adiposity indices should be noted in assessing a particular 
cardiometabolic disease.
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Background
Obesity is a major cardiovascular risk factor that has 
been a consistent global concern in modern time [1]. 
Recent epidemiologic evidence points to increased prev-
alence of overweight and obesity in most nations, but 
more notably in developing countries, with no reports 
of improvement since 1980 [2]. The Middle-Eastern 
region, Kingdom of Saudi Arabia (KSA) in particular, is 
not spared from this epidemic. It has been projected that 
obesity in KSA amongst adults will increase from 12% 
in 1992 to 41% by 2022 in males, and from 21 to 78% in 
females [3]. This observation is supported by a parallel 
increase in cardiometabolic diseases in the country [4].
Obesity has been conventionally defined as hav-
ing a body mass index (BMI) of >30  kg/m2. Several 
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anthropometric indices have also been used to define 
obesity based on fat distribution. These include waist 
circumference, waist-hip ratio and waist-to-height ratio, 
with each measure having their own advantages in pre-
dicting serious chronic non-communicable diseases and 
overall mortality [5–7]. Aside from these routine anthro-
pometric indices, novel adiposity measures have also 
been proposed and are currently being tested in different 
populations. These include body adiposity index (BAI) 
proposed by Bergman and colleagues [8] and visceral adi-
posity index proposed by Amato and colleagues [9].
To date, BAI has been assessed in several populations 
as an alternative risk factor for several cardiometabolic 
diseases [10–12], while preliminary findings employing 
VAI as a surrogate marker for adipose tissue function 
hold promise mostly in insulin-resistance related dis-
eases, such as diabetes mellitus type 2 (DMT2) [13, 14]. 
The comparison of BMI to the other adiposity indices 
mentioned above have not been carried out in the Arab 
population, while such studies have been done only par-
tially in other ethnic populations. In fact, the combina-
tion of 5 adiposity indices (waist, WHR, WhTr, BAI and 
VAI) as opposed to BMI in determining hard outcomes 
have never been investigated in a large-scale setting. The 
present study, therefore, aims to identify the sensitivity 
of all five adiposity indices in determining DMT2, coro-
nary heart disease (CHD), dyslipidemia, hypertension 
and metabolic syndrome (MetS) in the Arab population 
using two different cohorts gathered in 2008–2009 and 
2013–2014.
Methods
This is a descriptive, cross-sectional study involving 
two independent cohorts (2008–2009 and 2013–2014) 
of adult Saudis, which were obtained from the master 
database of the Biomarkers Research Program (BRP), 
College of Science, King Saud University (KSU), Riyadh, 
Saudi Arabia. A combined total of 9,769 subjects aged 
18–70 years (N = 5,356 from the 2008–2009 cohort and 
N  =  4,413 from the 2013–2014 cohort) were included. 
Ethics approval for both cohorts was obtained from the 
Ethics Committee of the College of Science, KSU, Riyadh, 
KSA.
Subjects from the 2008–2009 cohort
Participants from the 2008–2009 group were part of a 
joint collaborative project between BRP and the Minis-
try of Health (Riyadh Cohort Database) consisting of 
more than 17,000 Saudis aged 1–70 years, who were ran-
domly recruited from different households in the capi-
tal Riyadh, Saudi Arabia [4]. Non-ambulatory patients, 
expectant mothers and those that required immediate 
medical attention were excluded. A general questionnaire 
was administered to all participants with assistance from 
the research team. This questionnaire contained demo-
graphic information that included age and family history. 
Anthropometrics included height in meters and weight 
in kilograms, measured while patients were standing 
upright and with light clothing. Waist circumference was 
obtained using a standardized measuring tape rounded 
off to the nearest centimeter, measured midway between 
the lowest rib and iliac crest after normal expiration, 
while hip circumference was measured at the level of the 
greater trochanters as done previously [15]. Fasting blood 
samples were collected on the same day in the near-
est primary care center. Written informed consent was 
obtained prior to inclusion.
Subjects from the 2013–2014 xohort
Participants from the 2013–2014 group were taken from 
the on-going joint collaborative project between BRP and 
the Ministry of Education, which involved teachers and 
students from different public schools within Riyadh, 
Saudi Arabia, which began in 2013. A general question-
naire similar to that employed in the 2008–2009 cohort 
was administered and the same anthropometrics (height, 
weight, blood pressure, waist and hip circumference) 
were obtained following the same protocol of the 2008–
2009 cohort. Fasting blood samples were taken by the 
school nurse. Non-consenting subjects were not included 
and similar exclusion criteria as in the 2008–2009 cohort 
were applied for participation in the study.
Blood sample analyses
Fasting blood samples of both cohorts were analyzed and 
stored in BRP, KSU. In brief, all blood and serum sam-
ples were placed in plain polystyrene tubes, delivered on 
the same day at BRP and stored at −20°C. Fasting blood 
glucose and lipids (total cholesterol, triglycerides and 
HDL-cholesterol) were measured using a standard chem-
ical analyzer (hexokinase and colorimetric methods, 
respectively) (Konelab, Vantaa, Finland) under strict con-
ditions. The analyser was recalibrated frequently accord-
ing to manufacturer’s instructions. LDL-cholesterol was 
estimated using the Friedwald equation [Total Choles-
terol − (HDL − Cholesterol + (Triglycerides/2.2)] [16].
Diagnosis of cardiometabolic diseases
Diagnosis of DMT2 was based on both the proposed 
cut-offs by the American Diabetes Association and by 
the World Health Organization (WHO) [fasting plasma 
glucose (FPG) level ≥7.0  mmol/L (126  mg/dL)] [17], as 
well as documented history of DMT2 (e.g., known DMT2 
cases, use of anti-DMT2 drugs). CHD patients were 
known cases based on medical history of abnormal angi-
ography, echocardiography, stress tests, history of cardiac 
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catheterization or by-pass surgery and use of commonly 
used CHD medications (aspirin, β-blockers, ACE inhibi-
tors, antiarrhythmic drugs, etc.). Adult hypertension was 
based on the consensus of the Seventh Joint National 
Committee on Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure (≥140/90 mmHg) [18] 
and from use of anti-hypertensive medications. Dyslipi-
demia was diagnosed according to the National Choles-
terol Education Program-Third Adults Treatment Panel 
(NCEP ATP III) [triglycerides ≥1.7  mmol/L with HDL 
cholesterol <1.03  mmol/L for men and <1.29  mmol/L 
for women]. Obesity was defined as BMI >30 kg/m2 [19]. 
Screening for MetS was done using the definition pro-
posed by the International Diabetes Federation, which 
takes into consideration ethnic-specific cut-offs for waist 
circumference [20].
Database cleaning and subject categorization
All subjects from both cohorts were initially categorized 
into 30 groups (Additional file 1: Table S1) based on the 
cardiometabolic disease present in each subject. These 
groups were downsized into five (Control, CHD, Diabe-
tes, Dyslipidemia and HTN). Patients with DMT1 and 
GDM were excluded. All those with CHD as a single dis-
ease and with other comorbidities were combined as a 
single group. All those with DMT2 as a single disease and 
with other comorbidities except CHD were combined as 
a single group. All subjects with dyslipidemia and with 
other comorbidities except CHD and DMT2 were com-
bined and all subjects who were hypertensive and/or 
obese were combined in one group. Obese or overweight 
subjects with none of the four cardiometabolic diseases 
were combined with controls. Subjects with missing 
information and with incomplete anthropometrics, glu-
cose and lipid indices were excluded from the database, 
leading the final study sample size to N = 6,821 [2008–
2009  N =  3,971 (1698 males and 2,273 females); 2013–
2014 N = 2,850 (926 males and 1,924 females)]. Figure 1 
shows the flow diagram of the breakdown of subjects.
Adiposity indices calculations
Body mass index (BMI) was computed as weight (kg) 
divided by height in squared meters (m2). Waist-Hip ratio 
was obtained as the quotient of waist (cm) divided by 
hip (cm) circumferences. Waist to height ratio was cal-
culated as waist (cm) over height (cm). Body adiposity 
index (BAI) was calculated as proposed by Bergman and 
colleagues [8] [hip circumference (cm) divided by (height 
(m)1.5  −  18]. Visceral adiposity index (VAI) was calcu-
lated based on the gender-dependent proposed formula 
by Amato and colleagues [9]:
Data analyses
Statistical analyses were done using SPSS version 21.0 
(SPSS Inc., Chicago, IL, USA). Continuous variables were 
presented as mean  ±  standard deviation and frequen-
cies were expressed as percentages (%). All variables were 
checked for normality using the Kolmogorov–Smirnov 
test. Independent samples Student t test was done for 
comparisons between categorical parameters between 
cohorts. VAI was log transformed prior to t testing due 
to its non-Gaussian distribution. Bivariate Spearman’s 
correlation analysis was done to determine significant 
associations between cardiometabolic risk factors and 
adiposity indices while adjusting for multiple compari-
sons. Receiver Operating Characteristic (ROC) analy-
ses were used to determine the area under ROC curves 
(AUC) between each cardiometabolic risk factor and adi-
posity index. P values for ROC were adjusted for multi-
ple comparisons (Bonferroni corrected p value = 0.008). 
All tests were 2-tailed and p values were set depending 
on the threshold required to achieve a type 1 error rate 
of 0.05.
Results
Table 1 shows the anthropometric and metabolic profile 
of the different cohorts. Prevalence of DMT2 and MetS 
were higher in the 2013–2014 than the 2008–2009 cohort 
(42.7 versus 28.7%, 58.5 versus 41.5%, respectively). 
Prevalence of other chronic diseases were low in both 
cohorts. The 2013–2014 cohort subjects were signifi-
cantly older and had significantly higher mean adiposity 
indices, blood pressure, glucose, triglycerides and HDL-
cholesterol than the 2008–2009 cohort (p values <0.001). 
The 2008–2009 cohort, on the other hand, had a signifi-
cantly higher mean VAI and LDL-cholesterol than the 
2013–2014 cohort (p values <0.001). The complete list of 
subjects based on their medical conditions is provided in 
Additional file 1: Table S1.
Table  2 shows the bivariate associations of the differ-
ent adiposity indices, including weight, to cardiometa-
bolic risk factors in all subjects. Age was most strongly 
associated with WHtR (R  =  0.47; p  <  0.001) followed 
by waist circumference (R  =  0.46; p  <  0.001) and least 
VAI in Females = [Waist/{36.58+ (1.89 × BMI)}]
× [Triglycerides/0.81]
× [1.52/HDL− Cholesterol]
VAI in Males = [Waist/{39.68+ (1.88 × BMI)}]
× [Triglycerides/1.03]
× [1.31/HDL− Cholesterol]
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with BAI (R =  0.16; p  <  0.001). Height had the strong-
est inverse association with BAI (R −0.74; p  <  0.001) 
followed by WHtR (R  =  −0.26; p  <  0.001) and BMI 
(R = −0.19; p < 0.001). Both systolic and diastolic blood 
pressures were strongly correlated with waist circumfer-
ence (R =  0.31 and 0.28, respectively) and weakly, with 
BAI (R  =  0.06 and 0.05, respectively). Fasting glucose 
levels were significantly associated with all indices but 
strongest with waist circumference and VAI, both having 
a R =  0.34. As for the lipids, triglycerides, HDL-, LDL- 
and total cholesterol had the strongest associations with 
VAI (R = 0.77, −0.62, 0.16 and 0.21, respectively). Both 
triglycerides and total cholesterol had the weakest asso-
ciations with BAI, while HDL-cholesterol had the weak-
est correlation with WHtR and BMI and LDL with WHR.
The AUCs of the different adiposity indices of the two 
cohorts to the cardiometabolic diseases are presented in 
Table 3. The most sensitive adiposity index to determine 
Fig. 1 Flow diagram for the selection of subjects in both cohorts.
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DMT2 was VAI (AUC = 0.72) in the 2008–2009 cohort, 
while waist and WHR were the most sensitive anthro-
pometric indices for DMT2 in the 2013–2014 cohort 
(AUCs  =  0.70). WHR was consistently the most sensi-
tive index to determine CHD in both the 2008–2009 and 
2013–2014 cohorts (AUCs = 0.70 and 0.84, respectively). 
For hypertension, WHtR and BMI were more sensitive 
than other indices (AUCs = 0.66 and 0.58, respectively), 
but with poor predictability. Weight had the highest AUC 
for dyslipidemia (AUC = 0.73) in the 2008–2009 cohort, 
but none in the 2013–2014 cohort. Lastly, waist circum-
ference had the highest AUC for MetS (AUC  =  0.85) 
followed closely by WHtR and VAI for the 2008–2009 
cohort, while in the 2013–2014 cohort VAI had the high-
est AUC (0.84), followed closely by waist circumference 
and WHtR, respectively.
Discussion
We investigated for the first time the sensitivity of all 
five adiposity indices, including BMI, in assessing risk 
for DMT2, CHD, hypertension, dyslipidemia and meta-
bolic syndrome in an adult Arab population on two sepa-
rate large-scale cohorts. First we observed that VAI was 
most predictive of DMT2 and MetS as compared to the 
other indices, including BMI, in cohorts 2008–2009 and 
2013–2014, respectively. Several studies on VAI confirm 
its significant association to glycemia-related biomark-
ers, including adipocytokines [13, 14] and has recently 
been proven to be a reliable indicator of overt metabolic 
syndrome [21]. While this finding is strongly in favor of 
VAI’s increasing clinical use, it is interesting to note that 
the concept of VAI for use in non-Caucasian populations 
needs to be further tested. VAI is a gender-specific model 
derived from BMI, waist circumference, triglycerides and 
HDL-cholesterol from healthy normal/overweight adult 
Caucasian populations [22], hence, its use in other eth-
nic groups, such as the ones used in this study should be 
interpreted with caution. The sensitivity of VAI to CHD 
was not far from WHR, especially in the 2013–2014 
cohort and this was somehow expected, as several cases 
in the CHD group harbor DMT2. It has been reported 
that CHD is more severe in patients with DMT2 and VAI 
is strongly associated with the severity of CHD [23].
With regards to the best adiposity index for determin-
ing CHD, WHR was superior among other indices, con-
firming the recent report of Mousavi in a Middle-Eastern 
population that WHR change was associated with inci-
dent mortality, something not observed with BMI and 
Table 1 General characteristics of subjects
Data presented as mean ± standard deviation; significant at p < 0.05.
Parameter 2008–2009 2013–2014 P value
N 3,971 2,850
M/F 1698/2,273 926/1,924
DM (%) 1,141 (28.7) 1,216 (42.7)
CHD (%) 51 (1.3) 12 (0.4)
Hypertension (%) 288 (7.3) 122 (4.3)
Dyslipidemia (%) 20 (0.5) 38 (1.3)
MetS (%) 1,649 (41.5) 1,668 (58.5)
Age (years) 40.3 ± 16.2 47.3 ± 13.9 <0.001
BMI (kg/m2) 28.8 ± 6.3 30.6 ± 6.4 <0.001
Waist (cm) 89.6 ± 21.0 94.1 ± 21.8 <0.001
Hips (cm) 100.3 ± 21.5 102.3 ± 21.1 <0.001
WHR 0.91 ± 0.2 0.93 ± 0.2 <0.001
WHtR 0.55 ± 0.1 0.59 ± 0.1 <0.001
Body Adiposity Index 30.9 ± 13.5 34.3 ± 14.9 <0.001
Visceral Adiposity Index 3.8 ± 3.9 3.4 ± 2.9 <0.001
Systolic blood pressure (mmHg) 120.4 ± 15.2 126.2 ± 16.6 <0.001
Diastolic blood pressure (mmHg) 76.8 ± 9.0 80.0 ± 10.9 NS
Glucose (mmol/L) 6.9 ± 3.8 7.8 ± 4.0 <0.001
Triglycerides (mmol/L) 1.67 ± 1.0 1.84 ± 1.2 <0.001
Total cholesterol (mmol/L) 5.0 ± 1.2 5.0 ± 1.2 NS
HDL‑cholesterol (mmol/L) 0.87 ± 0.4 1.0 ± 0.3 <0.001
LDL‑cholesterol (mmol/L) 3.4 ± 1.0 3.1 ± 1.0 <0.001
Table 2 Bivariate associations between adiposity indices and cardiometabolic risk factors
Data presented as coefficient (R); ** denotes significance at 0.005 level.
Parameter BMI Weight Waist WHR WHtR VAI BAI
Age (years) 0.28** 0.19** 0.46** 0.44** 0.47** 0.31** 0.16**
Height (m) −0.19** 0.33** 0.01 0.14** −0.26** 0.06** −0.74**
Systolic blood pressure (mmHg) 0.29** 0.27** 0.31** 0.29** 0.30** 0.19** 0.06**
Diastolic blood pressure (mmHg) 0.26** 0.27** 0.28** 0.23** 0.26** 0.17** 0.05**
Glucose (mmol/L) 0.24** 0.12** 0.34** 0.33** 0.33** 0.34** 0.10**
Triglycerides (mmol/L) 0.22** 0.19** 0.28** 0.28** 0.24** 0.77** 0.003
Total cholesterol (mmol/L) 0.16** 0.11** 0.14** 0.10** 0.15** 0.21** 0.08**
HDL‑cholesterol (mmol/L) −0.01 −0.12** −0.06** −0.14** 0.006 −0.62** 0.18**
LDL‑cholesterol (mmol/L) 0.10** 0.08** 0.08** 0.03** 0.08** 0.16** 0.05**
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waist circumference [24]. Our findings are also in accord-
ance with several studies done using different popula-
tions, asserting that WHR is superior to other indices, 
such as BMI, in predicting mortality and cardiovascular 
events [25–27]. Furthermore, it is somehow expected 
that WHR and waist circumference, markers of abdomi-
nal obesity, together with other indices that utilized waist 
circumference as part of the mathematical model (WHtR 
and VAI) to be better in predicting harder outcomes 
related to vascular health than BMI and BAI [28], with 
waist circumference alone being sensitive in determining 
dyslipidemia and MetS.
As mentioned previously, several populations have 
assessed the clinical significance of the various anthro-
pometric indices and attempted to determine which 
ones are best for use in the general population. In Sin-
gapore, where the general population was less heterog-
enous than that of our study, they found that BAI was 
not better than BMI or WHtR in identifying persons at 
risk for CVD [29]. This is in line with our present find-
ings, where BAI was the least sensitive in determining 
the cardiometabolic diseases studied. Furthermore, we 
found that WHtR was most sensitive, albeit quite mod-
est, in determining hypertension in the Arab popula-
tion, at least in the 2008–2009 cohort. This finding also 
supports the notion that probably, at least in the Arab 
population, WHtR can also be used as a predictor for 
hypertension, as several large-scale studies done in dif-
ferent ethnic groups also attest its superiority over BMI 
(and waist circumference) for detecting cardiometabolic 
risk factors [30–32].
It is important to highlight that the sensitivity of the 
various adiposity indices were determined and compared 
from two independent cohorts, with differences not only 
in time period but also in the subject selection. With the 
exception of WHR, which maintained supremacy over 
other indices in predicting CHD, overall, there was no 
“best” index, as the sensitivity levels of the adiposity indi-
ces were modestly near one another. Furthermore, VAI 
as a visceral fat function indicator is the only index used 
which contains blood parameters that directly affect vari-
ance in insulin resistance [33], hence, the bias in compar-
ison to anthropometric indices. What the present study 
clearly suggests is that measures of abdominal adiposity 
maybe more clinically relevant than BMI and BAI in their 
ability to detect cardiometabolic diseases in the Arab eth-
nic population. Abdominal fat accumulation has been 
consistently linked to cardiovascular prognosis and vas-
cular complications [34, 35]. In particular, visceral adi-
posity influences vascular health in its association with 
incident hypertension and its close associations to the 
cardiometabolic complications of obesity [36, 37], mak-
ing it a promising target of therapy for cardiometabolic 
diseases [38].
The authors acknowledge several caveats. The downsiz-
ing of the 30 original groups to 5 may have created bias 
in the sensitivity of adiposity indices. While it may have 
been ideal to assess the different diseases as a single entity 
without any comorbidity, the intention was to maximize 
the sample size since the other groups were smaller and 
combining them into a bigger group based on the pres-
ence of a single hard outcome (CHD, DM, etc.) may hold 
Table 3 Receiving operator characteristics of various adiposity indices and cardiovascular diseases
Data presented as AUC (95% confidence interval); ** denotes significance at 0.008 level.
ROCs in italics denote most sensitive adiposity index for a given cardiometabolic disease.
DM CHD HTN Dyslipidemia IDF (MetS)
2008–2009
BMI 0.612 (0.59–0.63)** 0.585 (0.51–0.66) 0.658 (0.62–0.69)** 0.707 (0.61–0.81)** 0.736 (0.72–0.75)**
Weight 0.618 (0.60–0.64)** 0.56 (0.49–0.528) 0.652 (0.619–0.685)** 0.730 (0.633–0.827)** 0.74 (0.725–0.756)**
Waist 0.650 (0.63–0.67)** 0.664 (0.59–0.74)** 0.655 (0.62–0.69)** 0.715 (0.63–0.80)** 0.851 (0.84–0.86)**
WHR 0.678 (0.66–0.70)** 0.705 (0.64–0.78)** 0.607 (0.57–0.64)** 0.685 (0.60–0.75)** 0.688 (0.67–0.706)**
WHtR 0.646 (0.62–0.67)** 0.674 (0.60–75)** 0.663 (0.63–0.70)** 0.687 (0.61–0.76)** 0.848 (0.835–0.861)**
VAI 0.715 (0.70–0.73)** 0.599 (0.51–0.69) 0.562 (0.53–0.60)** 0.672 (0.59–0.75)** 0.814 (0.80–0.829)**
BAI 0.507 (0.48–0.53) 0.541 (0.45–0.63) 0.579 (0.54–0.62)** 0.499 (0.38–0.62) 0.659 (0.64–0.677)**
2013–2014
BMI 0.596 (0.57–0.62)** 0.670 (0.55–0.79)** 0.583 (0.53–0.64)** 0.493 (0.41–0.57) 0.712 (0.69–0.733)**
Weight 0.585 (0.564–0.605) 0.351 (0.192–0.509) 0.569 (0.517–0.621) 0.465 (0.386–0.543) 0.675 (0.654–0.695)**
Waist 0.696 (0.68–0.72)** 0.795 (0.69–0.90)** 0.537 (0.48–0.60) 0.589 (0.52–0.66) 0.813 (0.795–0.832)**
WHR 0.695 (0.67–0.72)** 0.836 (0.72–0.95)** 0.494 (0.44–0.55) 0.589 (0.49–0.68) 0.70 (0.678–0.722)**
WHtR 0.688 (0.67–0.71)** 0.783 (0.69–0.88)** 0.553 (0.49–0.61) 0.586 (0.51–0.66) 0.808 (0.789–0.827)**
VAI 0.690 (0.67–0.71)** 0.800 (0.68–0.92)** 0.510 (0.45–0.57) 0.495 (0.42–0.57) 0.837 (0.82–0.853)**
BAI 0.563 (0.54–0.59)** 0.476 (0.37–0.58) 0.575 (0.52–0.63) 0.511 (0.42–0.61) 0.67 (0.644–0.688)**
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more strength than simply excluding the group from the 
analysis. Also, the findings did not include other relevant 
factors such as physical activity and diet, as well as other 
biomarkers of adiposity and diagnostic markers (HbA1c 
and imaging tests) in the assessment of adiposity indices. 
Nevertheless, the findings are robust and support other 
several large-scale studies that highlight the clinical sig-
nificance of the various anthropometric parameters com-
monly used in epidemiologic studies. It is also the first of 
its kind in the Arab population, where the incidence of 
cardiometabolic diseases are more common than in other 
groups, reinforcing ethnic-specific differences in the man-
ifestation of insulin resistance-related diseases [39].
In summary, we determined for the first time the sen-
sitivity of 6 anthropometric indices (BMI, waist, WHR, 
WHtR, BAI and VAI) in determining cardiometabolic 
diseases in the adult Arab population. In at least one 
cohort, VAI is most sensitive in determining DMT2 
and MetS (together with waist circumference), WHR in 
CHD, WHtR in hypertension and waist circumference 
in dyslipidemia, highlighting the importance of body fat 
distribution, abdominal obesity in particular, in assess-
ing overall cardiometabolic risk. These screening tools 
should be promoted for clinical use and their predictive 
values noted in assessing at risk Arab adults.
Authors’ contributions
NMA, OSA and SS conceptualized the study; AA, KW and AMA performed the 
experiments; SS performed statistics and wrote the manuscript; NMA, MSA, AA 
and GPC provided intellectual input and contributed to writing the final ver‑
sion of the manuscript. All authors read and approved the final manuscript.
Author details
1 Biomarkers Research Program, Biochemistry Department, College of Science, 
King Saud University, Riyadh 11451, Kingdom of Saudi Arabia. 2 Prince Mutaib 
Bin Abdullah Chair on Osteoporosis, Biochemistry Department, College of Sci‑
ence, King Saud University, PO Box, 2455, Riyadh 11451, Kingdom of Saudi 
Arabia. 3 Department of Clinical Lab Sciences, College of Applied Medical 
Sciences, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia. 4 First 
Department of Pediatrics, Athens University Medical School, 11527 Athens, 
Greece. 
Acknowledgements
The authors thank the Deanship of Scientific Research, Prolific Research Group Pro‑
gram (PRG‑1436‑15), Vice Rectorate for Graduate Studies and Scientific Research in 
King Saud University (KSU), Riyadh, Saudi Arabia for funding the study.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 28 May 2015   Accepted: 29 July 2015
Additional file
Additional file 1: Table S1. Subject classification distribution according 
to cohort.
References
 1. Morgen CS, Sorensen TI (2014) Obesity: global trends in the prevalence of 
overweight and obesity. Nat Rev Endocrinol 10(9):513–514
 2. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al 
(2014) Global, regional, and national prevalence of overweight and 
obesity in children and adults during 1980–2013: a systematic analysis for 
the Global Burden of Diseases Study in 2013. Lancet 384(9945):766–781
 3. Al‑Quwaidhi AJ, Pearce MS, Critchley JA, Sobngwi E, O’Flaherty M (2014) 
Trends and future projections of the prevalence of adult obesity in Saudi 
Arabia, 1992–2022. East Mediterr Health J 20(10):589–595
 4. Al‑Daghri NM, Al‑Attas OS, Alokail MS, Alkharfy KM, Yousef M, Sabico SL 
et al (2011) Diabetes Mellitus type 2 and other chronic non‑communi‑
cable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a 
decade of an epidemic. BMC Med 9:76
 5. Lim RB, Chen C, Naidoo N, Gay G, Tang WE, Seah D et al (2015) Anthropo‑
metrics indices of obesity, and all‑cause and cardiovascular disease‑
related mortality, in an Asian cohort with type 2 diabetes mellitus. 
Diabetes Metab [Epub ahead of print]
 6. Czernichow S, Kengne AP, Huzley RR, Butley GD, de Galan B, Grobbee D 
et al (2011) Comparison of waist‑hip ratio and other obesity indices as 
predictors of cardiovascular disease risk in people with type 2 diabetes: a 
prospective cohort study from ADVANCE. Eur J Cardiovasc Prev Rehabil 
18(2):312–319
 7. Cronin O, Morris DR, Walker PJ, Golledge J (2013) The association of obe‑
sity with cardiovascular events in patients with peripheral artery disease. 
Atherosclerosis 228(2):316–323
 8. Bergman RN, Stefanovski D, Buchanan TA, Summer AE, Reynolds JC, 
Sebring NG et al (2011) A better index of body adiposity. Obesity (Silver 
Spring) 19(5):1083–1089
 9. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M et al 
(2010) Visceral adiposity index: a reliable indicator of visceral fat function 
associated with cardiometabolic risk. Diabetes Care 33(4):920–922
 10. Djibo DA, Araneta MR, Kritz‑Silverstein D, Barrett‑Connor E, Wooten W 
(2015) Body adiposity index is a risk factor for the metabolic syndrome 
in postmenopausal Caucasian African American, and Filipina women. 
Diabetes Metab Syndr 9(2):108–113
 11. Garcia AI, Nino‑Silva LA, Gonzalez‑Ruiz K, Ramirez‑Velez R (2015) Body 
adiposity index as a marker of obesity and cardiovascular risk in adults 
from Bogota, Colombia. Endocrinol Nutr 62(3):130–137
 12. Yu Y, Wang L, Liu H, Zhang S, Walker SO, Bartell T et al (2015) Body mass 
index and waist circumference rather than body adiposity index are bet‑
ter surrogates for body adiposity in a Chinese population. Nutr Clin Pract 
30(2):274–282
 13. Amato MC, Giordano C (2014) Visceral adiposity index: an indicator of 
adipose tissue dysfunction. Int J Endocrinol 2014:730827
 14. Al‑Daghri NM, Al‑Attas OS, Alokail MS, Alkharfy KM, Charalampidis P, 
Livadas S et al (2013) Visceral adiposity index is highly associated with 
adiponectin and glycaemic disturbances. Eur J Clin Invest 43(2):183–189
 15. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concen‑
tration of low‑density lipoprotein cholesterol in plasma, without use of 
the preparative ultracentrifuge. Clin Chem 18:499–502
 16. Al‑Daghri N, Alokail M, Al‑Attas O, Sabico S, Kumar S (2010) Establish‑
ing abdominal height cut‑offs and their association with conventional 
indices of obesity among Arab children and adolescents. Ann Saudi Med 
30(3):209–214
 17. American Diabetes Association (2010) Diagnosis and classification of 
diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69
 18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al 
(2003) Seventh report of the joint national committee on prevention, 
detection, evaluation, and treatment of high blood pressure. Hyperten‑
sion 42:1206–1252
 19. Expert Panel on Detection (2001) Evaluation and Treatment of High 
Blood Cholesterol in Adults. Executive summary of the third report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detec‑
tion, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III). JAMA 285:2486–2497
 20. Alberti KG, Zimmet P, Shaw J (2005) IDF epidemiology task force consen‑
sus group. The metabolic syndrome: a new worldwide definition. Lancet 
366:1059–1062
Page 8 of 8Al‑Daghri et al. Cardiovasc Diabetol  (2015) 14:101 
 21. Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S et al (2014) 
Visceral adiposity index is predictive of an altered adipokine profile in 
patients with type 2 diabetes. PLoS One 9(3):e91969
 22. Amato MC, Giordano C (2013) Clinical indications and proper use of 
Visceral Adiposity Index. Nutr Metab Cardiovasc Dis 23:e31–e32
 23. Han L, Fu KL, Zhao J, Wang ZH, Tang MX, Wang J et al (2014) Visceral 
adiposity index score indicated the severity of coronary heart disease in 
Chinese adults. Diabetol Metab Syndr 6(1):143
 24. Mousavi SV, Mohebi R, Mozaffary A, Sheikholeslami F, Azizi F, Hadaegh F 
(2014) Changes in body mass index, waist and hip circumference, waist 
to hip ratio and risk for all‑cause mortality in men. Eur J Clin Nutr [Epub 
ahead of print]
 25. Myint PK, Kwok CS, Luben RN, Wareham NJ, Khaw KT (2014) Body fat 
percentage, body mass index and waist‑to‑hip ratio as predictors of 
mortality and cardiovascular disease. Heart 100(20):1613–1619
 26. De Koning L, Merchant AT, Pogie J, Anand SS (2007) Waist circumference 
and waist‑hip ratio as predictors of cardiovascular events: meta‑regres‑
sion analysis of prospective studies. Eur Heart J 28(7):850–856
 27. Czernichow S, Kengne AP, Stamatakis E, Hamer M, Batty GD (2011) Body 
mass index, waist circumference and waist‑hip ratio: which is the better 
discriminator of cardiovascular disease mortality risk?: evidence from 
an individual‑participant meta‑analysis of 82864 participants from nine 
cohort studies. Obes Rev 1299:680–687
 28. Lukich A, Gavish D, Shargorodsky M (2014) Normal weight diabetic 
patients versus obese diabetics: relation of over‑all and abdominal 
adiposity to vascular health. Cardiovasc Diabetol 13:141
 29. Lam BC, Koh GC, Chen C, Wong MT, Fallows SJ (2015) Comparison of 
body mass index (BMI), body adiposity index (BAI), waist circumference 
(WC), waist‑to‑hip ratio (WHR) and waist‑to‑height‑ratio as predictors of 
cardiovascular disease risk factors in an adult population in Singapore. 
PLoS One 10(4):e0122985
 30. Ashwell M, Gunn P, Gibson S (2012) Waist‑to‑Height ratio is a better 
screening tool than waist circumference and BMI for adult cardio‑
metabolic risk factors: systematic review and meta‑analysis. Obes Rev 
13(3):275–286
 31. Li WC, Chen IC, Chang YC, Loke SS, Wang SH, Hsiao KY (2013) Waist‑to‑
Height ratio, waist circumference, and body mass index as indices of car‑
diometabolic risk among 36,642 Taiwanese adults. Eur J Nutr 52(1):57–65
 32. Park YS, Kim JS (2012) Association between waist‑to‑height ratio and 
metabolic risk factors in Korean adults with normal body mass index and 
waist circumference. Tohoku J Exp Med 228(1):1–8
 33. Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X (2014) Clinical usefulness of 
lipid ratios, visceral adiposity indicators, and the triglycerides and glucose 
index as risk markers of insulin resistance. Cardiovasc Diabetol 13(1):146
 34. Zafrir B, Khashper A, Gaspar T, Dobrecky‑Mery I, Azencot M, Lewis BS et al 
(2014) Prognostic impact of abdominal fat distribution and cardiorespira‑
tory fitness in asymptomatic type 2 diabetics. Eur J Prev Cardiol [Epub 
ahead of print]
 35. Nagao H, Kashine S, Nishizawa H, Okada T, Kimura T, Hirata A et al (2013) 
Vascular complications and changes in body mass index in Japanese 
type 2 diabetic patients with abdominal obesity. Cardiovasc Diabetol 
12:88
 36. Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR et al (2014) 
The relationship of body mass index and fat distribution with incident 
hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol 
64(10):997–1002
 37. Farb MG, Gokce N (2015) Visceral adiposopathy: a vascular perspective. 
Horm Mol Biol Clin Investig 21(2):125–136
 38. Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB et al 
(2014) Visceral adiposity and the risk of metabolic syndrome across body 
mass index: the MESA study. JACC Cardiovasc Imaging 7(12):1221–1235
 39. Sulistyoningrum DC, Gasevic D, Lear SA, Ho J, Mente A, Devlin AM 
(2013) Total and high molecular weight adiponectin and ethnic‑specific 
differences in adiposity and insulin resistance: a cross‑sectional study. 
Cardiovasc Diabetol 12:170
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
